Cabometyx (cabozantinib)
pCPA File Number:
22062
Negotiation Status:
Under consideration for negotiation
Indication(s):
Treatment of adult patients with differentiated thyroid carcinoma (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory (RAI-R) or ineligible
Sponsor/Manufacturer:
Ipsen Biopharmaceuticals
CADTH Project Number:
PC0287
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable